News Agency
Men's Weekly

Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories

  • Written by PR Newswire
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories
  • Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.
  • The transaction is in furtherance of Kinnate's previously announced pursuit of strategic alternatives.
  • This acquisition is intended to enable Pierre Fabre Laboratories to pursue its efforts...

Read more: Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre...

Understanding Your Rights Around Property After Separation

Property division is one of the most significant financial matters that arises when a relationship ends, and it's also one of the most commonly misunderstood. Many people assume that assets are simply divided equally, but the reality under Australian family... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion